Trialbee strengthens its leadership by adding veteran life sciences executive Rick Riegel to its Board of Directors to support global growth in clinical trial patient recruitment.
Trialbee, a global leader in technology-enabled patient recruitment for clinical trials, has announced the appointment of accomplished life sciences executive Rick Riegel to its Board of Directors. The move reflects Trialbee’s ongoing commitment to strengthening its leadership structure and advancing its long-term strategy as the company continues expanding its influence across the global clinical research ecosystem. With decades of leadership experience across the life sciences, technology, and professional services industries, Riegel’s addition to the board is expected to further accelerate Trialbee’s growth, innovation, and operational excellence.
Strengthening Leadership During a Period of Rapid Growth
Clinical trials are becoming increasingly complex as pharmaceutical and biotechnology companies seek to develop innovative therapies while navigating regulatory requirements, patient diversity challenges, and evolving technological landscapes. One of the most persistent obstacles in clinical research remains patient recruitment and engagement. Delays in recruiting the right participants can significantly extend trial timelines and increase costs, making efficient recruitment strategies essential for the success of modern clinical development programs.
Trialbee has positioned itself as a pioneer in addressing this challenge through a technology-driven approach that combines advanced data analytics, artificial intelligence, and global digital outreach. By connecting sponsors, contract research organizations (CROs), and healthcare providers with suitable patients, the company helps streamline recruitment and accelerate clinical trial timelines.
The appointment of Rick Riegel to the board signals a strategic step forward for Trialbee as it seeks to strengthen its leadership capabilities and scale its global operations. With deep expertise in guiding high-growth organizations, Riegel will help support the company’s mission to transform patient recruitment and improve clinical trial enrollment outcomes worldwide.
Rick Riegel’s Extensive Leadership Background
Rick Riegel currently leads LMC Advisory, a firm he established to provide board-level advisory and consulting services to investors and organizations focused on high-growth opportunities in the life sciences sector. Through LMC Advisory, Riegel works closely with companies navigating expansion, transformation, and strategic positioning in a competitive and rapidly evolving industry.
Over the course of a career spanning more than three decades, Riegel has built an impressive track record of leadership in both established corporations and high-growth technology companies. His experience includes serving as Chief Executive Officer of Phlexglobal and LIQUENT, two organizations that played important roles in the life sciences services ecosystem.
During his tenure at these companies, Riegel led transformative growth initiatives and successfully guided both organizations through strategic exits. Phlexglobal was acquired by Vitruvian Partners, while LIQUENT was acquired by PAREXEL. These transactions highlighted Riegel’s ability to scale organizations, enhance their market positioning, and create significant value for stakeholders.
Beyond his CEO roles, Riegel has also held senior leadership positions across several prominent organizations. He served as General Manager and Head of Sales and Marketing in the technology and professional services sectors for companies such as IBM, First Consulting Group, Taratec Development, and Barnett International. These roles provided him with extensive experience in commercial strategy, technology adoption, and operational leadership across global markets.
Supporting Trialbee’s Mission to Transform Patient Recruitment
As a member of Trialbee’s Board of Directors, Riegel will contribute his expertise in scaling high-growth technology organizations and navigating complex life sciences markets. His insights are expected to help the company strengthen its partnerships with pharmaceutical sponsors and expand its enterprise relationships with leading global drug developers.
Trialbee’s platform leverages advanced data capabilities and AI-powered technology to identify and connect eligible patients with clinical trials more efficiently than traditional recruitment methods. By combining targeted digital outreach with predictive analytics, the company enables sponsors and CROs to accelerate patient enrollment and improve trial performance.
Trialbee CEO Matt Walz expressed enthusiasm about the appointment, emphasizing both Riegel’s professional expertise and his longstanding relationship with the organization.
According to Walz, Riegel has consistently demonstrated the ability to guide organizations through periods of growth while maintaining strong strategic focus and delivering meaningful value to customers. He noted that Riegel’s experience will play a vital role as Trialbee continues its mission to redefine global patient recruitment and help clinical research organizations achieve better enrollment outcomes.
Walz also highlighted a personal connection, explaining that Riegel has served as both a mentor and an advisory board member since Walz joined Trialbee as CEO. His appointment to the formal Board of Directors, Walz said, marks an important milestone as the company enters its next phase of growth.
A Strong Presence in the Life Sciences Boardroom
In addition to his new role at Trialbee, Riegel currently serves on the boards of several other private equity-backed organizations operating within the life sciences and healthcare sectors. These include Deerfield Group, where he serves as Chairman, as well as Ametris, Syner-G BioPharma Solutions, and RealTime eClinical Solutions.
His work with these organizations reflects a broad expertise spanning commercial strategy, operational transformation, digital innovation, and scaling organizations to meet global demand. This breadth of experience is expected to be highly valuable to Trialbee as it continues expanding its global footprint and strengthening its technology platform.
Building Momentum for the Next Phase of Growth
Riegel expressed strong confidence in Trialbee’s leadership and strategic direction. He praised the company’s progress under Matt Walz’s leadership and highlighted the organization’s growing influence within the clinical trial industry.
According to Riegel, Trialbee has become a defining force in reshaping how pharmaceutical sponsors and CROs identify, recruit, and engage patients around the world. By leveraging data-driven insights and embedded artificial intelligence capabilities, the company has created a powerful platform that delivers measurable results for clinical research programs.
Riegel also noted that Trialbee’s expanding global presence and technology-driven approach are setting new industry standards for efficiency and performance in patient recruitment. He emphasized that these capabilities are particularly important at a time when the industry is striving to improve patient access to clinical trials while reducing delays and development costs.
Another factor supporting Trialbee’s momentum is the recent investment from Varsity Healthcare Partners. This strategic backing, Riegel said, reflects strong confidence in the company’s platform and long-term vision. The investment provides additional resources that will help Trialbee scale its technology, expand partnerships, and enhance its services for sponsors and CROs worldwide.
Advancing the Future of Clinical Trials
The global clinical trial landscape is evolving rapidly, driven by technological innovation, increased regulatory expectations, and the growing need for patient-centric research models. Companies like Trialbee are playing a crucial role in modernizing the clinical trial process by improving how patients are identified, recruited, and supported throughout their participation.
With Rick Riegel joining the Board of Directors, Trialbee is strengthening its leadership at a pivotal moment in the company’s development. His experience in guiding technology-driven life sciences companies through growth and transformation aligns closely with Trialbee’s mission to accelerate clinical research and improve patient access to potentially life-changing therapies.
As the company continues to expand its global reach and enhance its AI-powered platform, Trialbee aims to further redefine the standards of patient recruitment and engagement—helping bring new treatments to market faster while improving the overall efficiency of clinical trials.
With strategic leadership, strong investor support, and a rapidly advancing technology platform, Trialbee is well positioned to shape the future of patient recruitment and play an increasingly influential role in the global life sciences industry.